Effectiveness of 23-Valent Pneumococcal Polysaccharide Vaccine against Invasive Pneumococcal Disease in Adults, Japan, 2013–2017
Reiko Shimbashi, Motoi Suzuki

, Bin Chang, Hiroshi Watanabe, Yoshinari Tanabe, Koji Kuronuma, Kengo Oshima, Takaya Maruyama, Hiroaki Takeda, Kei Kasahara, Jiro Fujita, Junichiro Nishi, Tetsuya Kubota, Keiko Tanaka-Taya, Tamano Matsui, Tomimasa Sunagawa, Kazunori Oishi, and Adult IPD Study Group
Author affiliations: National Institute of Infectious Diseases, Tokyo, Japan (R. Shimbashi, M. Suzuki, B. Chang, K. Tanaka-Taya, T. Matsui, T. Sunagawa, K. Oishi); Tohoku University Graduate School of Medicine, Miyagi, Japan (R. Shimbashi, M. Suzuki, K. Oshima); Kurume University School of Medicine, Fukuoka, Japan (H. Watanabe); Niigata Prefectural Shibata Hospital, Niigata, Japan (Y. Tanabe); Sapporo Medical University School of Medicine, Hokkaido, Japan (K. Kuronuma); National Hospital Organization Mie National Hospital, Mie, Japan (T. Maruyama); Yamagata Saisei Hospital, Yamagata, Japan (H. Takeda); Nara Medical University, Nara, Japan (K. Kasahara); Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan (J. Fujita); Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan (J. Nishi); Kochi Medical School, Kochi University, Kochi, Japan (T. Kubota); Toyama Institute of Health, Toyama, Japan (K. Oishi)
Main Article
Table 2
Overall and serotype-specific effectiveness of PPSV23 against invasive pneumococcal disease in adults >20 years of age, Japan, 2013–2017*
Serotype |
No. cases |
No. controls |
Crude VE, % (95% CI) |
Adjusted VE,† % (95% CI) |
PPSV23 serotype |
746 |
375 |
46.0 (17.8 to 64.5) |
42.2 (13.4 to 61.4) |
PCV13, non–6A serotype |
392 |
375 |
40.6 (3.8 to 63.3) |
35.3 (−8.4 to 61.5) |
PPSV23, non–PCV13 serotype |
354 |
375 |
51.7 (18.7 to 71.3) |
44.5 (9.6 to 65.9) |
Serotype 3 |
152 |
375 |
43.1 (−11.9 to 71.1) |
34.1 (−34.4 to 67.7) |
Serotype 19A |
111 |
375 |
72.7 (29.1 to 89.5) |
70.3 (13.3 to 89.8) |
Serotype 12F |
99 |
375 |
80.2 (34.4 to 94.0) |
70.8 (1.0 to 91.4) |
Serotype 22F |
83 |
375 |
34.1 (−47.1 to 70.5) |
22.7 (−88.8 to 68.4) |
Serotype 10A |
80 |
375 |
75.7 (19.2 to 92.7) |
73.6 (5.9 to 92.6) |
Serotype 11A/E |
41 |
375 |
30.7 (−106.7 to 76.8) |
20.7 (−145.4 to 74.4) |
Serotype 7F |
30 |
375 |
31.5 (−138.6 to 80.3) |
22.4 (−176.8 to 78.2) |
Main Article
Page created: August 05, 2020
Page updated: September 17, 2020
Page reviewed: September 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.